Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2024 | The role of metabolic programming in CLL biology and the importance of studying lymph node cells

Eric Eldering • 27 Sep 2024
ERIC 2024
Chronic Lymphocytic Leukemia Leukemia

Eric Eldering, PhD, Amsterdam UMC Cancer Center, Amsterdam, Netherlands, highlights the importance of metabolism in cancer cells, particularly in chronic lymphocytic leukemia (CLL). He emphasizes that most researchers study CLL biology using blood cells, but these are metabolically inert, so it is more relevant to study lymph node cells. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Collaboration and/or sponsored research agreements with AstraZeneca, BMS, Genentech, Janssen.

More from Eric Eldering

The new concept of glutamine addiction in CLL and how it may contribute to drug resistance 2:24
The new concept of glutamine addiction in CLL and how it may contribute to drug resistance
Eric Eldering • 27 Sep 2024

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals